Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome is a disorder diagnosed on symptom-based criteria without inclusion of any objective parameter measurable by known diagnostic methods. Heterogeneity of the disorder and overlapping with more serious organic diseases increase uncertainty for the physician’s work and increase the cost of confirming the diagnosis. This paper is an attempt to summarize the efforts to find adequate biomarkers for irritable bowel syndrome, which should shorten the time to diagnosis and reduce the cost. Most of the reviewed papers were observational studies from secondary care institutions. Since publication of the Rome III criteria in 2006, most recent studies use these for the recruitment of IBS patients. This is a positive step forward as future studies should use the same criteria, facilitating comparison of their results. Among the studied biomarkers, most evidence is provided for fecal calprotectin. Cutoff values for fecal calprotectin have still to be investigated prior to inclusion in the irritable bowel syndrome diagnostic algorithm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, patients with severe IBS symptoms in the absence of organic disease could be subjected to unnecessary repeated tests.13,51”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762 · cited 1×
“In 2001, the term “biomarker” was defined as “a characteristic that is measured and evaluated as an indicator of normal biological processes, pathogenetic processes or pharmacologic responses to a therapeutic agent” [41].”
BackgroundCoates, M. D., Mahoney, C. R., Linden, D. R., Sampson, J. E., Chen, J., Blaszyk, H., Crowell, M. D., Sharkey, K. A., Gershon, M. D., & Mawe, G. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.013 · Cited by 765 · cited 1×
“showed that 50% of patients with IBD in long-standing remission have IBS-like symptoms [37].”
BackgroundAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694 · cited 1×
“Introduction Irritable bowel syndrome (IBS) is defined as a functional disorder of the lower gastrointestinal (GI) tract, which manifests as abdominal pain and/or discomfort accompanied by altered bowel function, in the absence of biochemical or structural pathology [1].”
BackgroundHigh-throughput diversity and functionality analysis of the gastrointestinal tract microbiota
Zoetendal, E. G., Rajilić-Stojanović, M., & de Vos, W. M. (2008) · Gut · doi:10.1136/gut.2007.133603 · Cited by 673 · cited 1×
“Altered fecal microbiota is described in a subset of patients with IBS compared with healthy controls [24, 25].”
BackgroundAssessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study
RØseth, A. G., Fagerhol, M. K., Aadland, E., & Schjønsby, H. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011186 · Cited by 669 · cited 1×
“It is released into the intestine during colonic inflammation and is resistant to colonic degradation so it can easily be measured in stool [58].”
BackgroundDinan, T. G., Quigley, E. M. M., Ahmed, S. M. M., Scully, P., O’Brien, S., O’Mahony, L., O’Mahony, S., Shanahan, F., & Keeling, P. W. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.033 · Cited by 636 · cited 1×
“showed an increased number of IL-6 and IL-8 in IBS subgroups (diarrhea predominant, constipated, and alternators) [15].”
BackgroundCollins, S. M., & Bercik, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.075 · Cited by 612 · cited 1×
“The brain-gut axis (BGA) consists of the peripheral neuroendocrine system, central nervous system, particularly the autonomic nervous system, and the hypothalamic-pituitary-adrenal (HPA) axis [31].”
BackgroundDunlop, S. P., Jenkins, D., Neal, K. R., & Spiller, R. C. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.028 · Cited by 583 · cited 1×
“The authors suggest that this finding could be the result of enterochromaffin cell hyperplasia found in PI-IBS patients [54, 55].”
BackgroundTHABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 441 · cited 2×
“mention that cutoff FC levels of 30mg/kg combined with Rome I criteria can serve as a clear proof of IBS with no need for further examination [61].”
BackgroundMethod
Cited by
Hustoft, T. N., Hausken, T., Ystad, S. O., Valeur, J., Brokstad, K., Hatlebakk, J. G., & Lied, G. A. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.12969 · Cited by 218
Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment
Berg, P., & McCallum, R. W. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3839-x · Cited by 162
“IBS is suggested after at least 3 months of episodic abdominal pain, provided two of the next three criteria are present: Changes in the stool consistency are present, changes in stooling frequency are present, and abdominal pain is relieved by defecation [7].”
BackgroundFaecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?
Farup, P. G., Rudi, K., & Hestad, K. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0446-z · Cited by 103
“Inflammatory Bowel Disease) and healthy volunteers, but so far none has been judged as satisfactory for the use in daily practice [5, 6].”
BackgroundMethodResultFukui, H., Nishida, A., Matsuda, S., Kira, F., Watanabe, S., Kuriyama, M., Kawakami, K., Aikawa, Y., Oda, N., Arai, K., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082403 · Cited by 88
“With regard to diagnosis, although some objective molecular markers based on blood, stool, and intestinal tissue sampling have been proposed, no valid biomarkers of IBS have yet been established [3].”
BackgroundGuagnozzi, D., Arias, Á., & Lucendo, A. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13573 · Cited by 69
“IBS, and, in the absence of a colonoscopy with colonic mucosal biopsies, there is no marker for an accurate differential diagnosis between the two conditions.(14) Currently, diagnosis of IBS is symptom-based, with diagnostic criteria for each IBS-subtype as well as for functional diarrhoea.”
BackgroundVolatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach
Baranska, A., Mujagic, Z., Smolinska, A., Dallinga, J. W., Jonkers, D. M. A. E., Tigchelaar, E. F., Dekens, J. A. M., Zhernakova, A., Ludwig, T. G., Masclee, A., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13654 · Cited by 67
“The diagnosis of IBS is symptombased, using the Rome III criteria,(3) and objective and validated biomarkers are lacking.(4) When available, the ideal biological marker should differentiate IBS patients from healthy individuals and from patients with organic GI diseases, such as inflammatory bowel diseases (IBD).”
MethodIbrahim, N. K., Al-Bloushy, R. I., Sait, S., Al-Azhary, H. W., Bar, N. H. A., & Mirdad, G. A. (2016) · Libyan Journal of Medicine · doi:10.3402/ljm.v11.30866 · Cited by 44
“In addition, there are no diagnostic investigations or biomarkers for diagnosis of IBS, and it can be diagnosed only clinically by symptom-based criteria (5).”
BackgroundJang, A., Hwang, S.-K., Padhye, N. S., & Meininger, J. C. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17017 · Cited by 35
“In contrast, patients with severe IBS symptoms in the absence of organic disease could be subjected to unnecessary repeated tests.(13,51) Therefore, more reliable objective biomarkers are needed to supplement pathophysiologic disease status to assess the efficacy of certain therapies and avoid unnecessary invasive tes…”
BackgroundAmin, H. S., Irfan, F., Karim, S. I., Almeshari, S., Aldosari, K. A., Alzahrani, A. M., Almogbel, A. T., Alfouzan, S. M., & Alsaif, A. A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_43_21 · Cited by 34
“[12] Moreover, there are no definite diagnostic investigations or biomarkers and the diagnosis is usually made clinically by symptoms‐based criteria.[13] The worldwide prevalence of IBS is 11.”
BackgroundHippocampal AMPAR s involve the central sensitization of rats with irritable bowel syndrome
Chen, A., Chen, Y., Tang, Y., Bao, C.-J., Cui, Z., Xiao, M., & Lin, C. (2017) · Brain and Behavior · doi:10.1002/brb3.650 · Cited by 34
Bennet, S., Palsson, O. S., Whitehead, W. E., Barrow, D. A., Törnblom, H., Öhman, L., Simrén, M., & van Tilburg, M. A. L. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13378 · Cited by 33
Glioplasticity in irritable bowel syndrome
Lilli, N. L., Quénéhervé, L., Haddara, S., Brochard, C., Aubert, P., Rolli‐Derkinderen, M., Durand, T., Naveilhan, P., Hardouin, J.-B., GIORGIO, R. D., et al. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13232 · Cited by 23
Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
Romero-Mascarell, C., Fernández‐Esparrach, G., de Miguel, C. R., Masamunt, M. C., García-Rodríguez, S., Rimola, J., Urpí, M., Casanova, G., Ordás, Í., Ricart, E., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12092226 · Cited by 22
A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers
Nilsen, T. I. L., Sunde, K., Hansson, L., Havelka, A. M., & Larsson, A. O. (2016) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22061 · Cited by 19
Hafiz, T. A., Alhemayed, T. S., Mandorah, R. H., Alshanqiti, A. A., Almohaimeed, R. A., & Noor, O. M. (2023) · Cureus · doi:10.7759/cureus.39568 · Cited by 13
“In addition, IBS cannot be diagnosed with diagnostic investigations or biomarkers [28]; it can be diagnosed only through clinical trials or by excluding other diseases [29].”
BackgroundNutritional Status and Selected Adipokines in Children with Irritable Bowel Syndrome
Roczniak, W., Szymlak, A., Mazur, B., Chobot, A. P., Stojewska, M., & Oświęcimska, J. M. (2022) · Nutrients · doi:10.3390/nu14245282 · Cited by 7
“Since IBS symptoms also occur in many other diseases, a specific and sensitive marker for IBS would certainly make the diagnosis easier and more cost effective [67,68].”
BackgroundIrritable bowel syndrome (IBS) among Lebanese adults: unidentified IBS and associated factors
Yazbeck, G., Malaeb, D. N., Shaaban, H. S., Dine, A. S. E., Hallit, S. R., & Hallit, R. R. (2023) · BMC Public Health · doi:10.1186/s12889-023-16543-5 · Cited by 9
“The etiology of IBS is still unknown, but certain risk factors have been linked to its pathogenesis [2].”
BackgroundTursi, A., Brandimarte, G., Mario, F. D., Elisei, W., & Picchio, M. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.272.fef · Cited by 6
Delgado‐Herrera, L., Banderas, B. F., Ojo, O. R., Kothari, R., & Zeiher, B. G. (2017) · Patient Related Outcome Measures · doi:10.2147/prom.s126605 · Cited by 5
“Positive overall opinion 25 (100) 0 0 Look of questions 20 (80) 4 (16) 1 (4) • Small font made questions hard to read (n=4) Icons 22 (88) 2 (8) 1 (1) • Different color would help them stand out more (n=1) • Icons not responsive enough to the touch (n=1) • Suggestion to change icons on the opening “report history” scre…”
Background“Bullying in Incognito Mode”: The evolution of sibling bullying
Chandran, S., Prakrithi, S., Prakash, K. G., & Kishor, M. R. (2019) · Indian Journal of Social Psychiatry · doi:10.4103/ijsp.ijsp_44_18 · Cited by 5
Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota
Cosimato, I., Brescia, A., Franci, G., Casolaro, V., & Folliero, V. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020197 · Cited by 4
“Diagnosis is mainly based on clinical evaluation of symptoms, while instrumental and endoscopic examinations are mainly used to rule out other organic conditions [37].”
Síndrome del intestino irritable: lo (pen)último sobre lo que se está investigando
Domingo, J. J. S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.10.010 · Cited by 4
Abdel‐Qader, D. H. (2024) · National Journal of Community Medicine · doi:10.55489/njcm.150220243630 · Cited by 4
Liver stiffness better predicts portal hypertension after HCV eradication
Radu, C., Stancu, O., Sav, R., Bugariu, A., Suciu, A., Grigoras, C., Procopeț, B., Ştefănescu, H., & Sparchez, Z. A. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.272.hcv · Cited by 4
Palaniswamy, K. R. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250287 · Cited by 3
Expert opinion on current issues and challenges in irritable bowel syndrome
Lawate, P. S. (2024) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20241640 · Cited by 3
Proteomics analysis of IBS-D with spleen and kidney yang deficiency
Li, Y., Xiaolan, S., Wu, P., Wang, J., Guo, Y., Zhu, J., Wang, Q., Chen, J., Yang, F., & Wei, W. (2017) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2017.05.006 · Cited by 3
Yu, L.-M., Zhang, Y., Wang, Y.-W., Ye, W., & Lu, B. F. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i13.538 · Cited by 2
Irritable Bowel Syndrome Among University Students in JordanPreprint
Al-Shdaifat, A., Al-Kassar, A., Johannessen, A., Al-Dabbagh, Z., Al-Ethawi, M., Al-Obaidi, F., & El-Halabi, I. (2019) · Research Square · doi:10.21203/rs.2.11508/v1 · Cited by 2
“There are no biomarkers or specific investigations to confirm its presence; hence, the diagnosis is based on the symptoms and the exclusion of other disorders (5).”
BackgroundMihai, C., Mihai, B. M., Dranga, M., Drug, V. L., Covic, A. C., & Prelipcean, C. C. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.272.hyp · Cited by 1
Ismael, A., Ali, W. M., & Noraldeen, M. Y. (2022) · Kirkuk journal of medical sciences · doi:10.32894/kjms.2022.133974.1027 · Cited by 1
Loganathan, P., Diaz, J. R., & McCallum, R. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00018-9 · Cited by 1
Irritable bowel syndrome: the next-to-last that is being investigated
Domingo, J. J. S. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.05.004 · Cited by 1
Tanović, N. (2015) · Acta Medica Academica · doi:10.5644/ama2006-124.149
Diagnoses of Exclusion in the Workup of Abdominal Complaints
Watkins, J. W., & Lewis, Z. (2021) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2021.07.010
Volatile organic compounds analysis in the context of gastrointestinal health and disease
Baranska, A. L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20211129ab · Cited by 1
Bustamante-Bernal, M. A., Berg, P., & McCallum, R. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66030-0
Lakhtakia, S., Katrevula, A., & Katukuri, G. R. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20254245
Biomarkers in Irritable Bowel Syndrome: Bridging Gut–Brain Mechanisms to Precision Care
Goyal, M. K., Goyal, O., Chowdhary, R., Sehgal, T., Brahmandam, G., Parikh, A., Rampurawala, I. M., Vuthaluru, A. R., Goyal, P., & Issak, A. (2026) · Current Gastroenterology Reports · doi:10.1007/s11894-026-01053-2
“Emerging evidence discusses the role of low-grade inflam - mation in the pathogenesis of IBS, specifically epithelial dysfunction and visceral hypersensitivity [ 20 ].”
Metadata
- Authors
- Plavšić, I., Hauser, G., Tkalčić, M., Pletikosić, S., & Salkić, N.
- Affiliations
- Klinički Bolnički Centar Rijeka (HR)
- University of Rijeka (HR)
- Department of Gastroenterology and Hepatology, University Clinical Centre Tuzla, Trnovac bb, 76000 Tuzla, Bosnia and Herzegovina
- Corresponding author
- Hauser, Goran
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-12
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- PMC
- PMC4480928
- OpenAlex
- W1586847156
- Cited by
- 37
- References
- 71
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 3
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Gastroenterology Research and Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- irritable bowel syndrome, biomarkers, diagnosis, fecal calprotectin, Rome III criteria, diagnostic algorithm, diagnostic accuracy, differential diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.